ORIC Pharmaceuticals, Inc. (ORIC) Reports High ORR, Plans Phase 3 in 1L EGFR Atypical NSCLC

ORIC Pharmaceuticals reported Phase 1b data for enozertinib in 1L EGFR atypical NSCLC, showing 84% systemic and 70% intracranial ORR. The company plans to start the Phase 3 Redwood-1 trial in 1H 2027. According to ORIC, this marks a transition to late-stage development for enozertinib.

Original reporting
Published Oct 23, 2026, 7:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ORIC Pharmaceuticals, Inc. (ORIC) Reports High ORR, Plans Phase 3 in 1L EGFR Atypical NSCLC — source image
Decision brief

The 30-second read

$ORICBullishHigh
01

Why it matters

The Phase 1b data provides a tangible catalyst that could move the stock ahead of the planned Phase 3 start.

02

Market read

First‑report of strong Phase 1b results creates immediate trading interest.

03

What to watch

Regulatory timelines and competition from other EGFR inhibitors may temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

ORIC is a clinical‑stage biotech focused on EGFR‑mutated non‑small cell lung cancer.

Company-level read

Ticker impact

$ORICBullishHigh confidence
Context

ORIC reported Phase 1b data for enozertinib showing 84% systemic ORR and 70% intracranial ORR and announced a Phase 3 start in H1 2027.

Expected impact

likely upward pressure as market prices in the favorable response rates.

Evidence & confidence

Phase 1b results with high response rates are rare and suggest a competitive edge over existing EGFR therapies.

Market effects

Positive data may boost sentiment in the broader oncology biotech sector.

U.S. biotech investors likely to react, limited regional effect.

Potential impact on global EGFR‑targeted therapy pipelines.

Counterpoint

If later‑stage trials fail to confirm efficacy, the early hype could reverse sharply.

Key entities

  • ORIC Pharmaceuticals, Inc.

    Developer of enozertinib for EGFR‑atypical NSCLC.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo